Halozyme Therapeutics: Q2 Earnings Insights

 

Halozyme Therapeutics HALO reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM.

Here's what investors need to know about the announcement.

Earnings

Halozyme Therapeutics beat estimated earnings by 6.0%, reporting an EPS of $0.53 versus an estimate of $0.5.

Revenue was up $15.91 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.02 which was followed by a 0.99% increase in the share price the next day.

Here's a look at Halozyme Therapeutics's past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 0.49 0.41 0.42 0.40
EPS Actual 0.47 0.42 0.55 0.66
Revenue Estimate 128.25M 100.32M 101.94M 103.16M
Revenue Actual 117.28M 102.00M 115.83M 136.46M

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Guidance

Halozyme Therapeutics management provided guidance for FY 2022, expecting earnings between $2.1 and $2.25 per share.

To track all earnings releases for Halozyme Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!